Frontiers in Drug Discovery – HyBryte™ use in early-stage cutaneous T-cell lymphoma

An article describing the potential use of HyBryte™ in the treatment of cutaneous T-cell lymphoma (CTCL) published in Frontiers in Drug Discovery. The mini-review summarizes findings about the use, mechanism and effectiveness of HyBryte™ in the treatment of CTCL with a particular emphasis on the ability of HyBryte™ to address the unmet medical need in patients with early-stage disease. Read the publication.